Circulating Tumor DNA-based Minimal Residual Disease Detection in Colorectal Cancer Management : Episode 9
Clinical Utility of ctDNA Testing
Panelists explore the clinical value of circulating tumor DNA testing at various stages of the colorectal cancer treatment journey, with a focus on optimal testing timelines.
- What it the clinical utility of ctDNA throughout the treatment journey for CRC?
- At what time points and frequency is ctDNA testing most valuable?
- Do the time points of these tests differ between high- and low-risk patients?
Recent Videos
Related Content
FDA Approves Encorafenib/Cetuximab Plus mFOLFOX6 for Advanced BRAF V600E+ CRC
December 20th 2024Article
The FDA has granted accelerated approval to encorafenib in combination with cetuximab and mFOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation, as detected by an FDA-approved test.
